Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization

Journal of Neuroscience Research

Volumn 93, Issue 5, 2015, Pages 755-765

  Lee, Yujeong ^a   Park, Hee Ra ^a   Chun, Hye Jeong ^a   Lee, Jaewon ^a  

^a Pusan National University   (South Korea)

Author keywords

Mitochondrial membrane potentials; MPTP; Parkinson's disease; Silibinin

Indexed keywords

SILIBININ; ACTIN; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; ANTIOXIDANT; CALCIUM BINDING PROTEIN; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN; REACTIVE OXYGEN METABOLITE; SILYMARIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; MALE; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SILYBUM MARIANUM; ANIMAL; ANIMAL EMBRYO; BRAIN CORTEX; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; ANTIOXIDANTS; CALCIUM-BINDING PROTEINS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; EMBRYO, MAMMALIAN; MALE; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MITOCHONDRIA; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN; MOTOR ACTIVITY; MPTP POISONING; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SILYMARIN;

EID: 84925583817     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23544     Document Type: Article

References (30)

1. Abou-Sleiman PM, Muqit MM, Wood NW. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7:207-219.
2. Agarwal C, Tyagi A, Kaur M, Agarwal R. 2007. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28:1463-1470.
3. Baluchnejadmojarad T, Roghani M, Mafakheri M. 2010. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 480:206-210.
4. Barcia C. 2013. Glial-mediated inflammation underlying parkinsonism. Scientifica (Cairo) 2013:357805.
5. Borlongan CV, Martinez R, Shytle RD, Freeman TB, Cahill DW, Sanberg PR. 1995. Striatal dopamine-mediated motor behavior is altered following occlusion of the middle cerebral artery. Pharmacol Biochem Behav 52:225-229.
6. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453:49-62.
7. Choi SY, Son TG, Park HR, Jang YJ, Oh SB, Jin B, Lee J. 2012. Naphthazarin has a protective effect on the 1-methyl-4-phenyl-1, 2, 3, 4-tetrahydropyridine-induced Parkinson's disease model. J Neurosci Res 90:1842-1849.
8. Dawson TM, Ko HS, Dawson VL. 2010. Genetic animal models of Parkinson's disease. Neuron 66:646-661.
9. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A. 2000. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(Suppl 5):S21-S23.
10. + injection in rats. Pharmacol Biochem Behav 117:92-103.
11. Gegg ME, Cooper JM, Schapira AH, Taanman JW. 2009. Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One 4:e4756.
12. Haddadi R, Nayebi AM, Farajniya S, Brooshghalan SE, Sharifi H. 2014. Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. Daru 22:38.
13. Hirsch E, Graybiel AM, Agid YA. 1988. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334:345-348.
14. +-induced ROS generation and subsequent loss of dopaminergic cells. Brain Res 1469:129-135.
15. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. 1999. The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156:50-61.
16. Langston JW, Ballard PA Jr. 1983. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med 309:310.
17. Lee E, Park HR, Ji ST, Lee Y, Lee J. 2014. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1, 2, 3, 4-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-kappaB, ERK, and JNK. J Neurosci Res 92:130-139.
18. Lu P, Mamiya T, Lu L, Mouri A, Niwa M, Kim HC, Zou LB, Nagai T, Yamada K, Ikejima T, Nabeshima T. 2010. Silibinin attenuates cognitive deficits and decreases of dopamine and serotonin induced by repeated methamphetamine treatment. Behav Brain Res 207:387-393.
19. Maffei Facino R, Carini M, Aldini G, Berti F, Rossoni G, Bombardelli E, Morazzoni P. 1996. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 62:495-502.
20. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK. 2006. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 26:41-50.
21. Massano J, Bhatia KP. 2012. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med 2:a008870.
22. McGeer PL, McGeer EG. 2008. Glial reactions in Parkinson's disease. Mov Disord 23:474-483.
23. Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Lee D, Chung H, Oh MS, Lee KT, Park S. 2009. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 15:332-347.
24. Perez HJ, Carrillo SC, Garcia E, Ruiz-Mar G, Perez-Tamayo R, Chavarria A. 2014. Neuroprotective effect of silymarin in an MPTP mouse model of Parkinson's disease. Toxicology 319:38-43.
25. Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP. 2011. Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson's disease phenotype in the mouse. J Pineal Res 50:97-109.
26. Snyder SH, D'Amato RJ. 1985. Predicting Parkinson's disease. Nature 317:198-199.
27. Tipton KF, McCrodden JM, Sullivan JP. 1993. Metabolic aspects of the behavior of MPTP and some analogues. Adv Neurol 60:186-193.
28. Tota S, Kamat PK, Shukla R, Nath C. 2011. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav Brain Res 221:207-215.
29. Wang X, Petrie TG, Liu Y, Liu J, Fujioka H, Zhu X. 2012. Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem 121:830-839.
30. +-induced neurotoxicity via inhibition of mitochondrial-dependent apoptosis. J Neuroimmune Pharmacol 9:245-258.